The Latest in CLL

Idelalisib shows long-term safety, efficacy for relapsed CLL

April 26, 2019

Bendamustine/rituximab combo proves viable for comorbid CLL

April 10, 2019

Ibrutinib sustained responses in refractory CLL in long-term follow-up

March 27, 2019

Venetoclax and obinutuzumab induces deep responses in CLL

March 18, 2019

Short telomeres predict poorer response to chemo in CLL

March 15, 2019

CLL, GVHD may raise risk for skin cancer after allo-HCT

February 28, 2019

CLL

Targeted triplet shows potential for B-cell cancers

February 14, 2019

FDA approves ibrutinib plus obinutuzumab for CLL/SLL

January 28, 2019

CLL

Uninterrupted ibrutinib with CAR T could improve CLL outcomes

January 25, 2019

CLL

Obinutuzumab-based regimens yield durable remissions in CLL

January 16, 2019

CLL

Adding umbralisib to ibrutinib produced responses in MCL, CLL

January 10, 2019

MD Anderson–led alliance seeks to advance leukemia drug development

January 9, 2019

CLL

Armored CAR protects T cells, induces remissions

January 4, 2019

Long-term side effects of CAR T cells mostly mild

January 4, 2019

CLL at ASH: A ‘mountain of data’ for targeted therapies

December 19, 2018

CLL